A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (NCT04006808) — Spain Trial Details

Condition(s) studied

Herpes Zoster

Investigational drug(s) / intervention(s)

PED-HZ/su

PED-HZ/su: GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.

Study summary

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

Eligibility

Sex

ALL

Min age

1 Year

Max age

17 Years

Healthy volunteers

No

Inclusion Criteria: * Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol * Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure. * Written informed assent obtained from the subjects when applicable according to local requirements. * A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1) * Body weight ≥ 6 kg/13.23 pounds. * A subject is eligible if they meet at least one of the following criteria: * Documented previous VZV vaccination OR * Medically verified varicella (with source documentation) OR * Seropositive for VZV prior to transplantation. * Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1) * Subject who has received an ABO compatible allogeneic renal transplant (allograft). * Subject with stable renal function with stability defined as \<20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements. * Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1). * Female subjects of childbearing potential may be enrolled in the study, if the subject * has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series Exclusion Criteria: Medical conditions * Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft * Evidence of recurrent primary kidney disease within the current allograft * Previous allograft loss secondary to recurrent primary kidney disease * History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted). * Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment * Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant * VZV serostatus unknown prior to transplant * Subjects with advanced chronic kidney disease * Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder) * Subjects without multiple dialysis options in the event acute or chronic dialysis needed. * History of unstable or progressive neurological disorder. * Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures * Subjects \> 5 years with history of one or more complex febrile seizures * Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1 * Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion: * IgA nephropathy * Rapidly progressive glomerulonephritis * Membranous glomerulonephritis * Idiopathic Type I membranoproliferative glomerulonephritis * Diabetes mellitus (type 1 and 2) with diabetic nephropathy * Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease * Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine * Any condition which, in the judgement of the investigator would make intramuscular injection unsafe. * Atypical Haemolytic Uraemic Syndrome. Prior/Concomitant therapy * Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period. * Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment. * Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study. * Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study. * Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study. * Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1. * Previous vaccination against HZ * Varicella vaccination within the 6 months (180 days) preceding Visit Day 1 * Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine Prior/Concurrent clinical study experience • Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product * available locally through compassionate use programs, * submitted for and pending local/country registration, * approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information * The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing Other exclusions * Child in care * Pregnant or lactating female * Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1. * Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and/or maintenance immunosuppressive therapies. * Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit * Completion must cover the 7 days immediately prior to randomisation (Visit Day 1). * Completion is defined as a minimum of 6 days completed. * Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1. * Any study personnel or their immediate dependants, family, or household member.

Primary outcome measure(s)

Number of subjects from the interventional groups, with solicited local adverse events (AEs) — Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
Assessed solicited local AEs are pain, redness and swelling at the injection site. Pain includes tenderness. Note: GSK diary cards for collecting solicited local and general AEs/symptoms is different for subjects \< 6 years and ≥ 6 years. Hence the age category of 1-11 years is further split to 1-5 years and 6-11 years.
Number of subjects from the interventional groups, with solicited general AEs — Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
Assessed solicited general AEs among Infants/Toddlers/Children \< 6 years are: * Drowsiness * Fever\* * Irritability/Fussiness * Loss of appetite * Gastrointestinal (GI) symptoms\*\* Assessed solicited general AEs among Children ≥ 6 years are: * Fatigue * Fever\* * GI symptoms\*\* * Headache * Myalgia * Shivering (chills) * Fever is defined as temperature ≥ 38.0°C/100.4°F \*\*GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain Note: GSK diary cards for collecting solicited local and general AEs/symptoms is different for subjects \< 6 years and ≥ 6 years. Hence the age category of 1-11 years is further split to 1-5 years and 6-11 years.
Number of subjects from the control groups with solicited general symptoms — Within 7 days after Visit Day 1
Assessed solicited general symptoms among Infants/Toddlers/Children \< 6 years are: * Drowsiness * Fever\* * Irritability/Fussiness * Loss of appetite * GI symptoms\*\* Assessed solicited general symptoms among Children ≥ 6 years are: * Fatigue * Fever\* * GI symptoms\*\* * Headache * Myalgia * Shivering (chills) * Fever is defined as temperature ≥ 38.0°C/100.4°F \*\*GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain As subjects from the control group are not vaccinated, they will not complete the diary card for local solicited symptoms.
Number of subjects from the control groups with solicited general symptoms — Within 7 days after Visit Month 1
Assessed solicited general symptoms among Infants/Toddlers/Children \< 6 years are: * Drowsiness * Fever\* * Irritability/Fussiness * Loss of appetite * GI symptoms\*\* Assessed solicited general symptoms among Children ≥ 6 years are: * Fatigue * Fever\* * GI symptoms\*\* * Headache * Myalgia * Shivering (chills) * Fever is defined as temperature ≥ 38.0°C/100.4°F \*\*GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain
Number of subjects from the interventional groups with unsolicited AEs after each vaccination — Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.
Number of subjects from the control groups with unsolicited symptoms — Within 30 days after Visit Day 1
An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.
Number of subjects from the control groups with unsolicited symptoms — Within 30 days after Visit Month 1
An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.
Number of subjects with serious adverse events (SAEs), potential immune mediated diseases (pIMDs) and biopsy confirmed renal allograft rejection. — From Visit Day 1 up to Visit Month 2
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. pIMDs are sub sets of Adverse events of special interest (AESIs) that include autoimmune disease and other inflammatory and/neurological disorders of interest, which may or may not have autoimmune aetiology. The renal allograft rejections are biopsy confirmed pathophysiological changes indicative of rejection. The rejection is graded for severity and extent of histologic inflammation and injury. The reporting period for any renal allograft rejection is from Visit Day 1 to the study end (month 2).
Number of subjects from the interventional groups with seizures — Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
All seizures occurring within 30 days following study vaccination are reported.
Number of subjects from the non-interventional groups with seizures — Within 30 days after Visit Day 1
All seizures occurring within 30 days after visit day 1 are reported, for the control groups.
Number of subjects from the non-interventional groups with seizures — Within 30 days after Visit Month 1
All seizures occurring within 30 days of visit month 1 are reported, for the control groups
Number of subjects from the interventional groups with generalized convulsive seizures — Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
Generalized convulsive seizures are classified as follows: * Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations * Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above * Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure.
Number of subjects from the non-interventional groups with generalized convulsive seizures — Within 7 days after Visit Day 1
Generalized convulsive seizures are classified as follows: * Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations * Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above * Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure
Number of subjects from the non-interventional groups with generalized convulsive seizures — Within 7 days after Visit Month 1
Generalized convulsive seizures are classified as follows: * Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations * Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations * Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above * Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure
Percentage of subjects with Anti-gE antibody concentrations in terms of Geometric Mean Concentrations (GMCs) — At Month 2 (one-month post-dose 2)
The geometric mean concentration (GMC) calculations are performed by taking the anti log of the mean of the log concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for GMC calculation

Trial sites (31)

Facility	City	Region	Status
GSK Investigational Site	Brussels	Belgium	Recruiting
GSK Investigational Site	Ghent	Belgium	Recruiting
GSK Investigational Site	Leuven	Belgium	Recruiting
GSK Investigational Site	Liège	Belgium	Recruiting
GSK Investigational Site	Bordeaux	France	Recruiting
GSK Investigational Site	Lille	France	Recruiting
GSK Investigational Site	Marseille	France	Recruiting
GSK Investigational Site	Montpellier	France	Recruiting
GSK Investigational Site	Nantes	France	Withdrawn
GSK Investigational Site	Paris	France	Recruiting
GSK Investigational Site	Paris	France	Recruiting
GSK Investigational Site	Toulouse	France	Recruiting
GSK Investigational Site	Genova	Italy	Completed
GSK Investigational Site	Milan	Italy	Recruiting
GSK Investigational Site	Padova	Italy	Recruiting
GSK Investigational Site	Roma	Italy	Recruiting
GSK Investigational Site	Torino	Italy	Recruiting
GSK Investigational Site	Gdansk	Poland	Recruiting
GSK Investigational Site	BaracaldoVizcaya	Spain	Recruiting
GSK Investigational Site	Espluges de Llobregat	Spain	Completed
GSK Investigational Site	HebrOn	Spain	Recruiting
GSK Investigational Site	Madrid	Spain	Recruiting
GSK Investigational Site	Madrid	Spain	Recruiting
GSK Investigational Site	Seville	Spain	Recruiting
GSK Investigational Site	Birmingham	United Kingdom	Completed
GSK Investigational Site	Cardiff	United Kingdom	Completed
GSK Investigational Site	Glasgow Strathclyde	United Kingdom	Recruiting
GSK Investigational Site	London	United Kingdom	Recruiting
GSK Investigational Site	Manchester	United Kingdom	Recruiting
GSK Investigational Site	Nottingham	United Kingdom	Recruiting
GSK Investigational Site	Southampton	United Kingdom	Recruiting

More GlaxoSmithKline trials in Spain

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy Active, not recruiting

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) Active, not recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma Active, not recruiting

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) Active, not recruiting

Other trials for the same condition

Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster Starting soon

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults Active, not recruiting